New test could prevent unneeded prostate cancer treatment

A new test from Genomic Health, the Oncotype DX Prostate Cancer Test, could reduce the number of men who undergo treatment for low-risk prostate cancer that would be better left untreated. The test rates the aggressiveness of a prostate biopsy based on an analysis of 17 genes and is more accurate than currently available tests, the developers say.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN